{"id":12858,"date":"2019-03-18T09:20:36","date_gmt":"2019-03-18T13:20:36","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12858"},"modified":"2019-03-18T09:20:36","modified_gmt":"2019-03-18T13:20:36","slug":"amarins-vascepa-prevents-second-and-third-heart-attacks-in-analysis-fueling-debate","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12858","title":{"rendered":"Amarin\u2019s Vascepa prevents second and third heart attacks in analysis, fueling debate"},"content":{"rendered":"<p>(By Matthew Herper for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">N<\/span><\/span>EW ORLEANS \u2014 A new analysis of a large study unveiled last November shows that\u00a0<a href=\"https:\/\/www.statnews.com\/2018\/11\/10\/detailed-results-amarin-fish-oil-major-cardiovascular-benefit\/\">Vascepa<\/a>, a fish-oil-derived drug sold by Amarin Pharmaceuticals, reduces second and third heart attacks as well as first ones.\u00a0 Continue reading <a href=\"https:\/\/www.statnews.com\/2019\/03\/18\/amarin-vascepa-fish-oil-heart-attacks\/\">article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Matthew Herper for STAT) NEW ORLEANS \u2014 A new analysis of a large study unveiled last November shows that\u00a0Vascepa,<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-12858","post","type-post","status-publish","format-standard","hentry","category-health-care-general"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12858"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12858\/revisions"}],"predecessor-version":[{"id":12859,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12858\/revisions\/12859"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}